-
-
A third stage of labor longer than 18 minutes is associated with a significant risk of postpartum hemorrhage. After 30 minutes the odds of having postpartum hemorrhage are 6 times higher than before 30 minutes.
-
Non-invasive prenatal diagnostic screening has become a hot topic of late. Large studies from England, Europe, and now 2 from the United States have borne out the efficacy of first trimester ultrasound determined nuchal translucency (NT) testing, with or without additional information provided by first trimester biochemical analysis (beta-hCG and PAPP-A).
-
Clinical trials for a male contraceptive that is a combination of progesterone and testosterone are expected to begin this year.
-
Use of risedronate in women 80 years and older reduced the incidence of vertebral fractures and was well tolerated.
-
African American women are far more likely to be infected with HIV than are white women and Hispanic women, a problem that has been growing, according to recent reports by the Centers for Disease Control and Prevention (CDC).
-
A spray-on birth control method for women recently has entered a Phase I clinical trial in which six women in Sydney, Australia, are using the new product as part of a study to determine whether the transdermal contraceptive can be used in spray formulation effectively.
-
The first male contraceptives to make it to the market likely will be hormonal-based birth control, similar to what has worked well for female contraceptives for the past four decades. However, there are serious difficulties with hormonal contraceptives for men, so the possibilities that are beginning to excite researchers working in the contraceptive field are the nonhormonal methods.
-
Its time to update your counseling on the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer; New York City). The Food and Drug Administration (FDA) has added a black box warning to the drugs labeling to highlight that prolonged use may result in the loss of bone mineral density (BMD).
-